Clinical Trial Update: Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic trial evaluating single-dose dolutegravir in HIV-seronegative subjects with severe hepatic impairment compared to matched controls has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatic Impairment

Drugs mentioned

• Dolutegravir (dolutegravir)

Snippet

Sponsor: Radboud University Medical Center | Conditions: HIV-1-infection, Hepatic Impairment | Phase 4 | Status: WITHDRAWN